Symbicort

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaRespiratory Tract InfectionBronchiectasisAllergic AsthmaCOPD

1050 competitors in Asthma

#DrugCompanyPhaseTrials

1

Symbicort

AstraZeneca

Approved

62

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

353

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

304

Spiriva

Boehringer Ingelheim

Preclinical

85

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

86

Atrovent

Boehringer Ingelheim

Preclinical

57

Formoterol Fumarate

AstraZeneca

Preclinical

88

Atrovent

Boehringer Ingelheim

Preclinical

29

Tylenol

KKenvue Brands

Preclinical

110

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1Show 10 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma6 trials

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

Completed·KKindeva Drug Delivery·Phase 3·NCT03015259·1,762 enrolled

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Completed·AstraZeneca·Phase 4·NCT04159519·170 enrolled

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Completed·AstraZeneca··NCT00573222·330 enrolled

Show 3 more trials

Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations

Completed·SStanford University·N/A·NCT01218399·10 enrolled

Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia

Completed·AstraZeneca·Phase 4·NCT00939341·862 enrolled

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Completed·AActavis Inc.·Phase 3·NCT02495168·1,714 enrolled

Tics1 trial

Effects of Symbicort on the Ventilatory Kinematics

Terminated·—·Phase 4·NCT01712854·9 enrolled

AIN1 trial

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

Completed·AstraZeneca··NCT00812682·217 enrolled

Bronchiectasis1 trial

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT02546297·90 enrolled

Obstructive Pulmonary Disease1 trial

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

Completed·AstraZeneca·Phase 3·NCT02157935·2,026 enrolled

5 more indications

Budesonide1 trial

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

Completed·AstraZeneca·Phase 3·NCT01360021·214 enrolled

Efficacy and Safety1 trial

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Completed·AstraZeneca·Phase 4·NCT00496470·660 enrolled

Respiratory tract infection1 trial

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Terminated·MMaisonneuve-Rosemont Hospital·Phase 2·NCT01432080·12 enrolled

Allergic Asthma1 trial

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Completed·SShanghai Biomabs Pharmaceutical Co., Ltd.·Phase 3·NCT03468790·393 enrolled

Exercise1 trial

U-LABA/ICS Effects on Exercise Performance, Formoterol

Completed·MMorten Hostrup, PhD·N/A·NCT06105671·20 enrolled

Details

Drug Info

Related News